This article is a revised and expanded version of the abstract entitled “Prognostic implications of p2y12 inhibitor pretreatment in non-ST-segment elevation acute coronary syndromes undergoing late invasive strategy—a national registry analysis” [26], which was presented at ESC Congress 2024, London, from 30 August to 2 September 2024. Here, P2RY12 is linked to acute coronary syndrome.